Blood cancers

CLL treatment goals in an evolving landscape: Prof Jan Burger and Prof Stephen Opat

Sponsored by Janssen-Cilag Pty Ltd

The treatment paradigm for CLL is evolving as new agents enter the landscape. While this is good news, it comes with its own set of challenges such as how to identify optimal sequence strategies and measure depth and durability of response. To understand where we’re at right now, we spoke to Professor Jan Burger from ...

Already a member?

Login to keep reading.

© 2021 the limbic